First patient dosed in Ph 1/2I study of MT-4561 in patients with advanced solid tumors
The Phase I/II study (NCT06943521), is a human, multicenter, open-label study, that evaluates safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of MT4561 in patients with advanced solid tumors. The clinical trial for MT-4561 will be conducted in 3 parts, across several sites, with the first part consisting of an intravenous infusion of MT-4561 once every week in 28-day cycle that evaluates the number of patients with adverse events and the incidence of dose limiting toxicities (DLT). The study details and doses of Part 2 (dose-optimization) and Part 3 (DrugDrug Interaction) will be available after review of applicable Part 1 results.
Share:
More News
Taiho Oncology, Inc. completed a New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) for zipalertinib in combination with platinum-based chemotherapy for the treatment of patients with previously untreated, locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20
“This collaboration reflects our conviction that atebimetinib has the potential to become an essential backbone therapy in a broad range of combinations across MAPK-driven cancers,” said Ben Zeskind, Immuneering CEO and co-founder. “Atebimetinib’s unique tolerability profile and broad activity make it well suited to combine with a wide range of
“These final updated results provide continued evidence of the potential for γδ T cell therapies to drive activity and improve outcomes for patients,” said William Ho, CEO and co-founder of IN8bio. “The clinical outcomes and observed activity are supported by our correlative analysis, including histopathology, demonstrating the expansion and persistence
“Patients with RAS-mutated mCRC have no first-line therapies specifically approved for their disease, and Fast Track designation reflects the potential of onvansertib to address this serious unmet need,” said Mani Mohindru, PhD, President and Chief Executive Officer of Cardiff Oncology. “Our randomized Phase 2 data give us confidence that onvansertib